- Home
- AVTX vs ALVR Comparison
AVTX vs ALVR Comparison
Compare AVTX & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- ALVR
- Stock Information
- Founded
- AVTX 2011
- ALVR 2013
- Country
- AVTX United States
- ALVR United States
- Employees
- AVTX N/A
- ALVR N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVTX Health Care
- ALVR Health Care
- Exchange
- AVTX Nasdaq
- ALVR Nasdaq
- Market Cap
- AVTX 90.9M
- ALVR 87.7M
- IPO Year
- AVTX 2015
- ALVR 2020
- Fundamental
- Price
- AVTX $10.13
- ALVR $0.55
- Analyst Decision
- AVTX Buy
- ALVR Sell
- Analyst Count
- AVTX 2
- ALVR 5
- Target Price
- AVTX $35.00
- ALVR $1.00
- AVG Volume (30 Days)
- AVTX 59.3K
- ALVR 595.8K
- Earning Date
- AVTX 11-07-2024
- ALVR 11-12-2024
- Dividend Yield
- AVTX N/A
- ALVR N/A
- EPS Growth
- AVTX N/A
- ALVR N/A
- EPS
- AVTX N/A
- ALVR N/A
- Revenue
- AVTX $820,000.00
- ALVR N/A
- Revenue This Year
- AVTX N/A
- ALVR N/A
- Revenue Next Year
- AVTX N/A
- ALVR N/A
- P/E Ratio
- AVTX N/A
- ALVR N/A
- Revenue Growth
- AVTX N/A
- ALVR N/A
- 52 Week Low
- AVTX $3.95
- ALVR $0.52
- 52 Week High
- AVTX $34.46
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- AVTX 37.71
- ALVR 36.38
- Support Level
- AVTX $12.00
- ALVR $0.52
- Resistance Level
- AVTX $13.59
- ALVR $0.64
- Average True Range (ATR)
- AVTX 0.96
- ALVR 0.09
- MACD
- AVTX -0.50
- ALVR -0.02
- Stochastic Oscillator
- AVTX 17.42
- ALVR 6.78
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.